Search
Greenwich Lifesciences Inc
GLSIAdd to Watchlist
22.000USD
-1.700-7.17%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
322.65MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Greenwich Lifesciences Inc is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 42.00, with a high of 45.00 and a low of 39.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
47.500
Target Price
+100.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Greenwich Lifesciences Inc
GLSI
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Greenwich Lifesciences Inc's price target?
Analysts forecast that Greenwich Lifesciences Inc's price target is USD 42.00, with the highest forecast at USD 45.00 and the lowest forecast at USD 39.00.
How have Greenwich Lifesciences IncGLSI's recent earnings per share performed?
The market expectation was USD -0.39, while Greenwich Lifesciences IncGLSI's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.34.
What is the analyst rating for Greenwich Lifesciences Inc?
Based on the ratings of Greenwich Lifesciences Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.